High erythroferrone expression in CD71


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
03 2021
Historique:
received: 11 10 2020
accepted: 14 12 2020
pubmed: 25 1 2021
medline: 10 8 2021
entrez: 24 1 2021
Statut: ppublish

Résumé

Ineffective erythropoiesis and iron overload are common in myelodysplastic syndromes (MDS). Erythroferrone (ERFE) and growth/differentiation factor 15 (GDF15) are two regulators of iron homeostasis produced by erythroid progenitors. Elevated systemic levels of ERFE and GDF15 in MDS are associated with dysregulated iron metabolism and iron overload, which is especially pronounced in MDS with SF3B1 gene mutations. However, the role of ERFE and GDF15 in MDS pathogenesis and their influence on disease progression are largely unknown. Here, we analyzed the expression of ERFE and GDF15 in CD71

Identifiants

pubmed: 33486765
doi: 10.1111/bjh.17314
doi:

Substances chimiques

Antigens, CD 0
CD71 antigen 0
Erfe protein, human 0
GDF15 protein, human 0
Growth Differentiation Factor 15 0
Peptide Hormones 0
Phosphoproteins 0
RNA Splicing Factors 0
Receptors, Transferrin 0
SF3B1 protein, human 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

879-891

Subventions

Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : 817/5-2
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : FOR2033
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : NICHEM
Organisme : Gutermuth Foundation
Organisme : H.W. & J. Hector foundation (Weinheim)
ID : M83
Organisme : Dr. Rolf M. Schwiete Foundation (Mannheim)
ID : 20/2016
Organisme : German José-Carreras-Foundation
ID : DJCLSH03/01

Informations de copyright

© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Références

Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107(1):55-63.
Gupta R, Musallam KM, Taher AT, Rivella S. Ineffective erythropoiesis: anemia and iron overload. Hematol/Oncol Clin. 2018;32(2):213-21.
Finkenstedt A, Bianchi P, Theurl I, Vogel W, Witcher DR, Wroblewski VJ, et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol. 2009;144(5):789-93.
Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-84.
Wang C, Fang Z, Zhu Z, Liu J, Chen H. Reciprocal regulation between hepcidin and erythropoiesis and its therapeutic application in erythroid disorders. Exp Hematol. 2017;52:24-31.
Lawen A. Is erythroferrone finally the long sought-after systemic erythroid regulator of iron? World J Biol Chem. 2015;6(3):78.
Seldin MM, Peterson JM, Byerly MS, Wei Z, Wong GW. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012;287(15):11968-80.
Bondu S, Alary A-S, Lefèvre C, Houy A, Jung G, Lefebvre T, et al. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med. 2019;11(500):eaav5467.
Camaschella C, Pagani A, Nai A, Silvestri L. The mutual control of iron and erythropoiesis. Int J Lab Hematol. 2016;38:20-6.
Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, et al. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res. 2014;38(5):545-50.
Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, et al. Dyserythropoiesis evaluated by the RED score and hepcidin: ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica. 2019;104(3):497-504.
Tanno T, Bhanu NV, Oneal PA, Goh S-H, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-101.
Ganz T. Erythropoietic regulators of iron metabolism. Free Radic Biol Med. 2019;133:69-74.
Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6(8):e23109.
Temraz S, Santini V, Musallam K, Taher A. Iron overload and chelation therapy in myelodysplastic syndromes. Crit Rev Oncol/Hematol. 2014;91(1):64-73.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25(4):402-8.
Mori Y, Chen JY, Pluvinage JV, Seita J, Weissman IL. Prospective isolation of human erythroid lineage-committed progenitors. Proc Natl Acad Sci USA. 2015;112(31):9638-43.
Dinh HQ, Eggert T, Meyer MA, Zhu YP, Olingy CE, Llewellyn R, et al. Coexpression of CD71 and CD117 identifies an early unipotent neutrophil progenitor population in human bone marrow. Immunity. 2020;53(2):319-34. e6.
Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329(1-2):9-22.
Dong HY, Wilkes S, Yang H. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A. Am J Surg Pathol. 2011;35(5):723-32.
Marsee DK, Pinkus GS, Yu H. CD71 (transferrin receptor) an effective marker for erythroid precursors in bone marrow biopsy specimens. Am J Clin Pathol. 2010;134(3):429-35.
Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014;99(6):956-64.
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et al. SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype-A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood. 2020;136(2):157-70.
Ganz T, Jung G, Naeim A, Ginzburg Y, Pakbaz Z, Walter PB, et al. Immunoassay for human serum erythroferrone. Blood. 2017;130(10):1243-6.
Kautz L, Jung G, Du X, Gabayan V, Chapman J, Nasoff M, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood. 2015;126(17):2031-7.
Huang Y, Liu R, Wei X, Liu J, Pan L, Yang G, et al. Erythropoiesis and iron homeostasis in non-transfusion-dependent thalassemia patients with extramedullary hematopoiesis. Biomed Res Int. 2019;2019:4504302.
Miura S, Kobune M, Horiguchi H, Kikuchi S, Iyama S, Murase K, et al. EPO-R+ myelodysplastic cells with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells. Blood Cells Mol Dis. 2019;78:1-8.
Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci USA. 1997;94(21):11514-9.
Ha G, De Torres F, Arouche N, Benzoubir N, Ferratge S, Hatem E, et al. GDF15 secreted by senescent endothelial cells improves vascular progenitor cell functions. PLoS One. 2019;14(5):e0216602.
Kim J, Kosak J, Kim J, Kissling G, Germolec D, Zeldin D, et al. NAG-1/GDF15 transgenic mouse has less white adipose tissue and a reduced inflammatory response. Mediators Inflamm. 2013;2013:641851.
Li M, Song K, Huang X, Fu S, Zeng Q. GDF15 prevents LPS and D-galactosamine-induced inflammation and acute liver injury in mice. Int J Mol Med. 2018;42(3):1756-64.
Otaka N, Shibata R, Ohashi K, Uemura Y, Kambara T, Enomoto T, et al. Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. Circ Res. 2018;123(12):1326-38.
Quandt D, Fiedler E, Boettcher D, Marsch WC, Seliger B. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res. 2011;17(10):3100-11.
Ratnam NM, Peterson JM, Talbert EE, Ladner KJ, Rajasekera PV, Schmidt CR, et al. NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J Clin Investig. 2017;127(10):3796-809.
Luan HH, Wang A, Hilliard BK, Carvalho F, Rosen CE, Ahasic AM, et al. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. 2019;178(5):1231-44. e11.

Auteurs

Vladimir Riabov (V)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Maximilian Mossner (M)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Alexandra Stöhr (A)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Johann-Christoph Jann (JC)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Alexander Streuer (A)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Nanni Schmitt (N)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Antje Knaflic (A)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Verena Nowak (V)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Nadine Weimer (N)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Julia Obländer (J)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Iris Palme (I)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Christiane Schumann (C)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Claudia D Baldus (CD)

Department of Hematology and Oncology, University Hospital Schleswig Holstein, Kiel, Germany.

Torsten J Schulze (TJ)

Institute Springe, German Red Cross Blood Service NSTOB, Springe, Germany.

Patrick Wuchter (P)

Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany.

Henning Röhl (H)

Department of Orthopedic Surgery, Diakonissen Hospital, Mannheim, Germany.

Ahmed Jawhar (A)

Department of Orthopedic Surgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Christel Weiss (C)

Department of Medical Statistics, Biomathematics and Information Processing, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Tobias Boch (T)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Georgia Metzgeroth (G)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Martin Neumann (M)

Department of Hematology and Oncology, University Hospital Schleswig Holstein, Kiel, Germany.

Wolf-Karsten Hofmann (WK)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Florian Nolte (F)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Daniel Nowak (D)

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH